What emerging trends in the FDA’s most coveted designations might tell us
Marked shifts in the pursuit and grant of high-order designations raise fascinating questions. What factors might be driving the sharp downturns in CDER breakthrough designations? And does the sharp post-pandemic upturn in high-order designations by CBER represent a shifting of enthusiasm in favor of advanced therapies? This report, analyzing recent data from the FDA, gives critical insights into market shifts in high-order designations and what it might mean for drug developers.
Related Insights
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Video
On-demand webinar: An expert guide to EU-CTR
Mar 10, 2022
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Article
Getting to ‘No’ fast is more important when you are small
Mar 4, 2022
Related Insights
Playbook
Early-phase development strategies for navigating regulatory complexity in the EU
Apr 29, 2024
Article
Near-term strategies for biotech drug developers facing shifting healthcare dynamics
Feb 14, 2024
Article
Expedited Pathways Comparisons - US EU CHN
Oct 19, 2021
Video
Overcoming asset transfer challenges during a merger and acquisition (M&A)
Oct 20, 2021
Article
8 things you need to know about eCTDs in China
Jul 1, 2022
Blog
Studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Nov 19, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Article
New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle
May 10, 2022
Video
On-demand webinar: An expert guide to EU-CTR
Mar 10, 2022
Blog
Maintaining Data Integrity for Quality and Compliance – Essential Despite Pandemic Disruptions
May 16, 2022
Article
Getting to ‘No’ fast is more important when you are small
Mar 4, 2022